BMRN
Biomarin Pharmaceutical
$55.75
−$0.20 (−0.36%)Oct 26, 2026
Key metrics
The numbers that frame BMRN today
- Market cap
- $10.79B
- P/E (TTM)
- 150.7
- EV / FCF
- 19.1
- Gross margin
- 76.1%
- EV / Sales
- 4.1
- ROIC
- 3.7%
- Div yield
- 0%
- Debt / equity
- 0.7
- 52wk Low
- $49.26
- 52wk High
- $70.98
Growth
Revenue and earnings trend for BMRN
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about BMRN
Is Biomarin Pharmaceutical a good buy?
Hold. Biomarin Pharmaceutical has strong momentum, but weak quality makes the setup mixed. Growth looks weak. That could put pressure on the long-term business case. We think Biomarin Pharmaceutical is selling at a fair price.
What is the market capitalization of BMRN?
Biomarin Pharmaceutical's market capitalization is $10.79B.
What is the P/E (TTM) ratio for BMRN stock?
Biomarin Pharmaceutical's P/E (TTM) ratio is 150.7, based on trailing earnings.
What is the 52-week high for BMRN stock?
The 52-week high for Biomarin Pharmaceutical is $70.98. The current close of $55.75 is 21.5% below that high.
What is the 52-week low for BMRN stock?
The 52-week low for Biomarin Pharmaceutical is $49.26. The current close of $55.75 is 13.2% above that low.
Does BMRN stock pay dividends?
Biomarin Pharmaceutical does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BMRN?
Biomarin Pharmaceutical's Debt / Equity ratio is 0.66.